Company Overview

MeiraGTx Holdings plc is a clinical-stage gene therapy company focused on developing and manufacturing genetic medicines for patients with severe and rare diseases. The company operates within the biotechnology and gene therapy industries, with a primary emphasis on adeno-associated virus (AAV)-based therapeutics. Its core business centers on discovering, developing, and producing gene therapies across multiple therapeutic areas, including ophthalmology, neurology, and diseases of the salivary glands.

Founded in 2015, MeiraGTx was established by a group of gene therapy researchers and executives with roots in academic research and prior biotechnology ventures. Since inception, the company has evolved from an early research-focused organization into a vertically integrated gene therapy developer with internal manufacturing capabilities. MeiraGTx’s strategy emphasizes control over vector design, manufacturing processes, and clinical development, which the company positions as a key competitive advantage in a capital- and expertise-intensive sector.

Business Operations

MeiraGTx generates value primarily through the development of a proprietary pipeline of gene therapy candidates and through strategic collaborations. Its operations are organized around therapeutic programs targeting inherited retinal diseases, neurodegenerative disorders, and conditions affecting secretory glands. The company’s revenue to date has largely been driven by collaboration and licensing arrangements rather than product sales, as none of its therapies have yet received full regulatory approval.

A central operational asset is MeiraGTx’s internal AAV manufacturing platform, which supports both clinical development and partnered programs. The company conducts operations in the United States and Europe and maintains a significant joint manufacturing initiative with a large pharmaceutical partner. Key subsidiaries and partnerships include MeiraGTx-Janssen Manufacturing, a joint venture established to develop large-scale, commercial-ready gene therapy manufacturing capabilities.

Strategic Position & Investments

MeiraGTx’s strategic direction is focused on advancing late-stage clinical programs while simultaneously scaling manufacturing technologies to support commercialization. A cornerstone of this strategy is its long-term collaboration with Janssen Pharmaceuticals, which includes co-development of gene therapies for inherited retinal diseases and investment in shared manufacturing infrastructure. This partnership represents both a major validation of MeiraGTx’s technology and a significant external investment in its platform.

The company continues to invest in next-generation vector design, novel promoters, and delivery approaches intended to improve durability and safety of gene therapies. Its pipeline spans multiple indications, reducing reliance on a single asset, and positions MeiraGTx to participate in emerging segments of the genetic medicine market. Where public disclosures do not clearly distinguish the future commercial allocation of certain partnered assets, data inconclusive based on available public sources.

Geographic Footprint

MeiraGTx is headquartered in London, United Kingdom, with substantial operations in the United States, particularly in New York. Its facilities and teams support research, clinical development, and manufacturing across these regions. The company’s geographic structure reflects its dual focus on European scientific origins and access to U.S. capital markets and clinical infrastructure.

Through international clinical trials, manufacturing activities, and strategic partnerships, MeiraGTx maintains an operational and investment presence across Europe and North America. Its collaborations with global pharmaceutical partners extend its influence into additional markets, although commercial market penetration remains contingent on future regulatory approvals.

Leadership & Governance

MeiraGTx is led by a management team with experience spanning biotechnology entrepreneurship, pharmaceutical development, and large-scale manufacturing. The leadership emphasizes scientific rigor, vertical integration, and long-term value creation through platform development rather than short-term asset monetization.

Key executives include:

• Alexandria Forbes – President and Chief Executive Officer
• Richard Giroux – Chief Financial Officer
• Neil Miller – Chief Scientific Officer
• Andrew Sturgess – Chief Operating Officer

The company’s governance structure reflects U.K. public company standards, with oversight provided by a board comprising executive and non-executive directors with backgrounds in life sciences, finance, and global pharmaceuticals.